Bruker has appointed Gerald Herman as interim CFO effective March 17. Herman was also recently appointed as principal accounting officer for the company, and he will assume his additional responsibilities as interim CFO following the departure of current CFO Anthony Mattacchione, whose resignation was announced in February. Herman joined the company in 2016 as vice president and corporate controller. Prior to that, he held senior executive positions with various publicly traded companies including Parexel International and Presstek.
Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.
Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital.
Rob Brainin, Hannes Smàrason
Rob Brainin has been appointed as WuXi NextCode's CEO, replacing Hannes Smàrason, who will stay on as a senior advisor and plans to pursue other entrepreneurial opportunities. Most recently, Brainin was the firm's executive vice president and COO. Prior to that, he held positions at Illumina, Thermo Fisher, Life Technologies, and Invitrogen. Brainin holds a degree in economics from Emory University and a JD degree from Harvard Law School.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.